American Heart Journal
Volume 155, Issue 4 , Pages 615-623 , April 2008

Highlights from American Heart Association, November 4 to 7, 2007, Orlando, FL: Late-breaking trials summary

References 

    Eptifibatide versus Abciximab in Primary PCI for Acute ST elevation Myocardial Infarction (EVA-AMI) trial
  1. Karvouni E, Katritsis DG, Ioannidis JPA. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. Journal of the American College of Cardiology. 2003;41:26–32
  2. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J. 2007;28:443–449
  3. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. The Lancet. 2000;356:2037–2044
  4. Roe MT, Ohman EM, Maas ACP, et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. Journal of the American College of Cardiology. 2001;37:9–18
    The Reperfusion of Acute MI in North Carolina Emergency Departments (RACE) Systems Improvement Program: Primary Results
  1. Jollis JG, Mehta RH, Roettig ML, et al. Reperfusion of acute myocardial infarction in North Carolina emergency departments (RACE): study design. Am Heart J. 2006;152:851-11
  2. Jollis JG, Roettig ML, Aluko AO, et al. Implementation of a Statewide System for Coronary Reperfusion for ST-Segment Elevation Myocardial Infarction. JAMA. 2007;298
    Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal Stenting in Massachusetts (MASS Stent)
  1. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356(10):1009–1019
  2. Jensen LO, Maeng M, Kaltoft A, et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007;50(5):463–470
  3. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357(14):1393–1402
    A Randomized Trial of Genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation (The Couma-Gen study)
  1. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med. 2003;138:714
  2. Carlquist JF, Horne BD, Muhlestein JB, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis. 2006;22:191
  3. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;(in press)

PII: S0002-8703(07)01001-0

doi: 10.1016/j.ahj.2007.12.001

American Heart Journal
Volume 155, Issue 4 , Pages 615-623 , April 2008

Article Tools